Chiara Tarantelli

Postdoctoral Researcher
Lymphoma Genomics
Oncology Institute of Southern Switzerland
Switzerland

Academician Genetics
Biography

Doctor of Philosophy (Ph.D.), Ph. D. in Oncology and Molecular and Clinical Pathology Company NameUniversity G. d'Annunzio Chieti-Pescara Dates EmployedJan 2010 – Apr 2013 Employment Duration3 yrs 4 mos Worked in a research team focused on the following projects: â–ª Molecular cross-talk between ErbB receptors and TGF-beta1 in human thyroid cancer; â–ª Identification of new immunological molecular targets in prostate cancer. Expertise in: extraction of DNA, RNA and proteins; electrophoresis of DNA, RNA and proteins; restriction enzyme digestions; protein determination assay (eg: Bradford, BCA); Western Blotting; Cell Culture, transfections; PCR, Real Time PCR, RT-PCR; Wound Healing Assay; Soft Agar Assay; Immunofluorescence; nucleic acid extraction from tissues; Coomassie and Silver staining and destaining; management of tissue and genetic material bank. Research fellowship Company NameUniversity G. d'Annunzio Chieti-Pescara Dates EmployedAug 2009 – Nov 2009 Employment Duration4 mos Research program: “Characterization of the Protein ZNF216, identified through SEREX technique in human prostate carcinomas”.

Research Intrest

Biochemistry, Life Sciences, Oncology, RT-PCR, Research, Western Blotting , DNA , Science, Cell Biology , Molecular Biology , Biotecnologia, Cell Culture , Immunofluorescenza , Reverse transcriptase-polymerase chain reaction, Biologia cellulase , Desossiribonucleico acid , Biochemical, Oncological

List of Publications
Tarantelli C, Gaudio E, Kwee I, Stathis A, Theocharous P, Zintl P, Zucca E, Bertoni F. Combinations containing the aza-anthracenedione pixantrone show preclinical activity in diffuse large B-cell lymphoma.
Tarantelli C, Gaudio E, Kwee I, Rinaldi A, Bernasconi E, Cascione L, Hillmann P, Stathis A, Carrassa L, Broggini M, Stussi G. Pre-clinical activity and mechanism of action of the novel dual PI3K/mTOR inhibitor PQR309 in B-cell lymphomas.
Tarantelli C, Gaudio E, Kwee I, Cascione L, Bernasconi E, Hillmann P, Stathis A, Stussi G, Fabbro D, Wicki A, Zucca E. The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas.